长期以来,由于世界上许多国家对头孢菌素新品种进行了大量研究工作,最近几年出现了许多重要新品种,如氨噻肟头孢菌素(HR756)、3—去甲酰氧甲基氨噻肟头孢菌素(FK749)、氧哌羟苯唑头孢菌素(T1551)、和羟羧氧酰胺菌素(6059s)等,目前均已有商品,这些新品种不仅像羟苄四唑头孢菌素(Cefmandole)、呋肟头孢菌素(Cefuroxi-me)、噻吩甲氧头孢菌素(Cefoxitin)一样对β—内酰胺酶高度稳定,而且具有较广的抗菌谱,尤其对革兰氏阴性杆菌具有更强的抗菌作用。在临床上对许多细菌性感染的治疗具有重要价值。但这些品种的共同缺点是对 For a long time, many countries in the world have done a lot of research on new cephalosporins. In recent years, many important new varieties have emerged, such as cefotaxime (HR756), 3-desoxymethylammonium Cefotaxime (FK749), oxyphenyloxacin cephalosporin (T1551), and oxycarboxamid (6059s), etc., are currently available, these new varieties not only like cefotaxime Cefmandole, Cefuroxi-me and Cefoxitin are highly stable to β-lactamase and have a broad antibacterial spectrum, especially against Gram-negative bacilli Has a stronger antibacterial effect. It is clinically valuable for the treatment of many bacterial infections. But the common disadvantage of these varieties is right